NNFA opens D.C. office
This article was originally published in The Tan Sheet
Executive Summary
Trade group's Washington, D.C. office opened April 30 to "expand advocacy efforts with federal legislators and regulators on behalf of its members and the natural products industry." NNFA Executive Director & CEO David Seckman is first to relocate to the new office, "which will initially deal primarily with government relations and public affairs," group says. NNFA, which has been planning the move for more than a year, will evaluate its staffing needs as time goes on; group retains its Newport Beach, Calif. office. D.C. branch is located at 1220 19th St. NW, Suite 400...
You may also be interested in...
Mr. Seckman goes to Washington
NNFA Executive Director & CEO David Seckman's lobbying efforts have targeted members of House Energy & Commerce Committee, which is investigating supplements including ephedra and andro. NNFA reports Seckman visited more than 30 Congressional offices in his first week in Washington, D.C. to educate members, staff on DSHEA and to promote message that FDA has sufficient authority to regulate supplements. Seckman also met with FDA Deputy Commissioner Lester Crawford, PhD, and others May 23 to discuss andro and other issues, such as FDA's authority under DSHEA. NNFA opened Washington office in April (1"The Tan Sheet" May 5, 2003, In Brief)...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.